Daisaku Hirano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daisaku Hirano has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Sadatsugu Minei
Department of Urology, Nihon University School of Medicine, Tokyo, Japan
5 shared publicationsToshio Yoshida
Department of Urology, Shonan Fujisawa Tokushukai Hospital, Kanagawa, Japan
5 shared publicationsKatsuhiko Satoh
Department of Urology, Nihon University School of Medicine, Tokyo, Japan
4 shared publicationsSatoru Takahashi
Department of Urology, Nihon University School of Medicine, Tokyo, Japan
4 shared publicationsShuji Sugimoto
Department of Urology, Higashi-matsuyama City Municipal Hospital, Higashi-matsuyama Saitama-ken, Japan; Department of Urology, Mitsui Hospital, Kawagoe Saitama-ken, Japan
4 shared publicationsTakahiko Hachiya
Department of Urology, Nihon University School of Medicine, Tokyo, Japan
4 shared publications
Latest Publications
- Open Access
- 1 August 2024
- Published by Sciencedomain International
- Vol. 7 (1) , 59-65
Renal Metachronous Metastasis from Adenocarcinoma of the Rectum: A Case Report and Review
Aim: Colorectal cancer metastasis to the kidney is extremely rare and the diagnosis of metastatic kidney tumor is challenging due to occasionally mimic primary renal tumors in imaging studies. We present a case of rectal cancer metastasis to the kidney and review the relevant literatures. Present of Case: A 51-year-old man was referred to our department due to a left renal tumor with size of approximately 3 cm in diameter detected by computed tomography (CT) during the follow-up after high anterior resection of the rectum for a rectal cancer and postoperative chemotherapy 5 years ago. Three years later after the initial treatments he had a metastasis in the left lung and underwent partial resection of the left lower lobe of the lung. Percutaneous renal tumor biopsies were conducted due to atypical renal tumor on the imaging diagnosis, and resulted in histologically tubular adenocarcinoma, representing rectal cancer metastasis. The imaging diagnosis showed no other metastasis. Therefore, he underwent left laparoscopic nephrectomy without any complications. Unfortunately, he had metastases of the lungs and died of cancer progression 19 months after the nephrectomy. Conclusions: There is the possibility of metastatic tumor to the kidney in patients with colorectal cancer when renal mass is found during routine follow-up. The prognosis seems to be poor in even undergoing surgical treatment such as nephrectomy like our case.
- 1 August 2024
- Published by Sciencedomain International
- Vol. 7 (1) , 59-65
Open AccessRenal Metachronous Metastasis from Adenocarcinoma of the Rectum: A Case Report and Review
Aim: Colorectal cancer metastasis to the kidney is extremely rare and the diagnosis of metastatic kidney tumor is challenging due to occasionally mimic primary renal tumors in imaging studies. We present a case of rectal cancer metastasis to the kidney and review the relevant literatures. Present of Case: A 51-year-old man was referred to our department due to a left renal tumor with size of approximately 3 cm in diameter detected by computed tomography (CT) during the follow-up after high anterior resection of the rectum for a rectal cancer and postoperative chemotherapy 5 years ago. Three years later after the initial treatments he had a metastasis in the left lung and underwent partial resection of the left lower lobe of the lung. Percutaneous renal tumor biopsies were conducted due to atypical renal tumor on the imaging diagnosis, and resulted in histologically tubular adenocarcinoma, representing rectal cancer metastasis. The imaging diagnosis showed no other metastasis. Therefore, he underwent left laparoscopic nephrectomy without any complications. Unfortunately, he had metastases of the lungs and died of cancer progression 19 months after the nephrectomy. Conclusions: There is the possibility of metastatic tumor to the kidney in patients with colorectal cancer when renal mass is found during routine follow-up. The prognosis seems to be poor in even undergoing surgical treatment such as nephrectomy like our case.
- Open Access
- 6 July 2022
- Published by Edorium Journals Pvt. Ltd.
- Vol. 7 (2) , 1-4
Huge multilocular spermatocele in a patient with left scrotal swelling
Introduction: Most spermatoceles are asymptomatic, unilocular, and small in size. They are typically cystic dilatations of the tubules of the efferent ductus in the head of the epididymitis, and less commonly dilatations of the tubules of the rete testis or aberrant ductus. However, huge spermatoceles are rare and to cause discomfort and cosmetic problems. Case Report: We present a case of a 42-year-old male with huge multilocular spermatocele mimicking hydrocele, who suffered from left scrotal enlargement for several years. Scrotal ultrasonography and magnetic resonance imaging (MRI) showed multilocular cystic spaces at the head of the left testis. Surgical exploration was performed and the size of the removal specimen was approximately 8.5×6.5×6.0 cm. The aspirated fluid contained spermatozoa, and histopathological and immunohistochemical examinations of the specimen showed a multilocular spermatocele arising from the epididymitis. He has been followed up without any significant complaints and recurrence one year after the surgery. Conclusion: It is important to keep in mind for spermatocele when encounter giant cystic diseases with multilocular appearance adjacent to the testicle. In such cases surgical exploration can be recommended.
- 6 July 2022
- Published by Edorium Journals Pvt. Ltd.
- Vol. 7 (2) , 1-4
Open AccessHuge multilocular spermatocele in a patient with left scrotal swelling
Introduction: Most spermatoceles are asymptomatic, unilocular, and small in size. They are typically cystic dilatations of the tubules of the efferent ductus in the head of the epididymitis, and less commonly dilatations of the tubules of the rete testis or aberrant ductus. However, huge spermatoceles are rare and to cause discomfort and cosmetic problems. Case Report: We present a case of a 42-year-old male with huge multilocular spermatocele mimicking hydrocele, who suffered from left scrotal enlargement for several years. Scrotal ultrasonography and magnetic resonance imaging (MRI) showed multilocular cystic spaces at the head of the left testis. Surgical exploration was performed and the size of the removal specimen was approximately 8.5×6.5×6.0 cm. The aspirated fluid contained spermatozoa, and histopathological and immunohistochemical examinations of the specimen showed a multilocular spermatocele arising from the epididymitis. He has been followed up without any significant complaints and recurrence one year after the surgery. Conclusion: It is important to keep in mind for spermatocele when encounter giant cystic diseases with multilocular appearance adjacent to the testicle. In such cases surgical exploration can be recommended.
- Open Access
- 15 January 2018
- Published by Wiley in Case Reports in Urology
- Vol. 2018, 1-4
A Case of Early Stage Bladder Carcinosarcoma in Late Recurrence of Urothelial Carcinoma after Transurethral Resection
Carcinosarcomas of the urinary bladder are rare biphasic neoplasms, consisting of both malignant epithelial and malignant mesenchymal components, and the prognosis of this tumor is unfavorable in most patients with even possibility of resection of disease. A 77-year-old male with a history of transurethral resection (TUR) of urothelial carcinoma (UC) of the bladder and adjuvant intravesical chemotherapy with pirarubicin 10 years ago revisited our department with a gross hematuria. Cystoscopy demonstrated an approximately 2.5 cm nonpapillary tumor on the right wall of the bladder. Pelvic MRI showed the tumor without extending the base of the bladder wall. The tumor could be completely removed with TUR. The malignant epithelial elements consisted of high-grade UC and the majority of mesenchymal components were fibrosarcomatous differentiation based on immunohistochemical studies. The tumor could be pathologically also suspected to be an early stage on TUR specimens. Although he has received no additional intervention due to the occurrence of myocardial infarction at three weeks after the TUR, he has been alive with no evidence of recurrence of the disease 27 months after the TUR. Some early stages of bladder carcinosarcoma might have a favorable prognosis without aggressive treatments.
- 15 January 2018
- Published by Wiley in Case Reports in Urology
- Vol. 2018, 1-4
Open AccessA Case of Early Stage Bladder Carcinosarcoma in Late Recurrence of Urothelial Carcinoma after Transurethral Resection
Carcinosarcomas of the urinary bladder are rare biphasic neoplasms, consisting of both malignant epithelial and malignant mesenchymal components, and the prognosis of this tumor is unfavorable in most patients with even possibility of resection of disease. A 77-year-old male with a history of transurethral resection (TUR) of urothelial carcinoma (UC) of the bladder and adjuvant intravesical chemotherapy with pirarubicin 10 years ago revisited our department with a gross hematuria. Cystoscopy demonstrated an approximately 2.5 cm nonpapillary tumor on the right wall of the bladder. Pelvic MRI showed the tumor without extending the base of the bladder wall. The tumor could be completely removed with TUR. The malignant epithelial elements consisted of high-grade UC and the majority of mesenchymal components were fibrosarcomatous differentiation based on immunohistochemical studies. The tumor could be pathologically also suspected to be an early stage on TUR specimens. Although he has received no additional intervention due to the occurrence of myocardial infarction at three weeks after the TUR, he has been alive with no evidence of recurrence of the disease 27 months after the TUR. Some early stages of bladder carcinosarcoma might have a favorable prognosis without aggressive treatments.
- 29 November 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (13) , e1719-e1720
Prognostic value of survivin in patients with urothelial carcinoma of the upper urinary tract
- 29 November 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (13) , e1719-e1720
Prognostic value of survivin in patients with urothelial carcinoma of the upper urinary tract
- 15 November 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (11) , e1487
Risk stratification for survival of upper urinary tract urothelial carcinoma after nephroureterectomy
- 15 November 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (11) , e1487
Risk stratification for survival of upper urinary tract urothelial carcinoma after nephroureterectomy
- Open Access
- 3 December 2015
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2015, 1-7
Metastatic Tumor of the Spermatic Cord in Adults: A Case Report and Review
Metastatic spermatic cord (SC) tumor is extremely rare. Recently, we experienced a case of late-onset metastatic SC tumor from cecal cancer. This case is a 68-year-old man presenting with a painless right SC mass. He had undergone a right hemicolectomy for cecal cancer 6 years ago. Radical orchiectomy and adjuvant chemotherapy with S-1 were performed. No recurrence was found after one year of follow-up. We identified a total of 25 cases, including our case, on a literature search via PubMed from January 2000 to April 2015. The most frequent primary sites of the tumors metastasizing to the SC were the stomach (8 cases, 32%) and the colon (8 cases, 32%), next the liver (2 cases, 8%), and kidney (2 cases, 8%). The majority of the cases underwent radical orchiectomy for the metastatic tumors of the SC. Over half of the cases received adjuvant interventions based on the regimens for the primary tumors. Prognosis in the patients with metastatic tumor of the SC was unfavorable except for late-onset metastasis. In patients with a mass in the SC and a history of neoplasm, especially in gastrointestinal tract, the possibility of metastasis from the primary cancer should be considered.
- 3 December 2015
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2015, 1-7
Open AccessMetastatic Tumor of the Spermatic Cord in Adults: A Case Report and Review
Metastatic spermatic cord (SC) tumor is extremely rare. Recently, we experienced a case of late-onset metastatic SC tumor from cecal cancer. This case is a 68-year-old man presenting with a painless right SC mass. He had undergone a right hemicolectomy for cecal cancer 6 years ago. Radical orchiectomy and adjuvant chemotherapy with S-1 were performed. No recurrence was found after one year of follow-up. We identified a total of 25 cases, including our case, on a literature search via PubMed from January 2000 to April 2015. The most frequent primary sites of the tumors metastasizing to the SC were the stomach (8 cases, 32%) and the colon (8 cases, 32%), next the liver (2 cases, 8%), and kidney (2 cases, 8%). The majority of the cases underwent radical orchiectomy for the metastatic tumors of the SC. Over half of the cases received adjuvant interventions based on the regimens for the primary tumors. Prognosis in the patients with metastatic tumor of the SC was unfavorable except for late-onset metastasis. In patients with a mass in the SC and a history of neoplasm, especially in gastrointestinal tract, the possibility of metastasis from the primary cancer should be considered.
- 1 April 2015
- Published by Elsevier in Asian Journal of Surgery
- Vol. 38 (2) , 79-84
Laparoscopic adrenalectomy for adrenal tumors: A 21-year single-institution experience
- 1 April 2015
- Published by Elsevier in Asian Journal of Surgery
- Vol. 38 (2) , 79-84
Laparoscopic adrenalectomy for adrenal tumors: A 21-year single-institution experience
- 8 April 2014
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 48 (5) , 436-444
Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy
The aim of this study was to prospectively verify the relationship between the clinical efficacies of secondary hormone therapy for castration-resistant prostate cancer (CRPC) following first line hormone therapy and neuroendocrine differentiation (NED). Forty-six consecutive patients with CRPC following first line hormone therapy who were treated with flutamide as secondary hormone therapy were prospectively assessed with a median follow-up of 21 months. Serum chromogranin A (CgA), as a marker of NED, was measured using an immunoradiometric assay. Of the 46 patients, 22 (48%) responded to the secondary hormone therapy as a 50% or more reduction from baseline prostate-specific antigen (PSA) with a median response duration of 9.2 months. The PSA response group was correlated with significantly favorable cancer-specific survival (CSS) (92% vs 59% at 5 years, p = 0.0146) compared with the non-response group. Above-normal CgA levels at study entry were detected in 15 patients (33%), but no association with CSS was identified. Data on CgA kinetics were available in 35 patients. The CgA levels before and at 3 months during the treatment were similar. However, eight patients (23%) with an increase in CgA level of a quarter or more from baseline had a tendency for worse CSS (63% vs 84% at 5 years, p = 0.0507) compared with the remaining patients. Within limitations, in this study secondary hormone therapy with flutamide was effective for CRPC following first line hormone therapy. The above-normal CgA level in the first hormone resistance phase is mostly unrelated to prognosis. However, some patients with a remarkable increase in CgA in a short duration may have an unfavorable prognosis caused by NED as well.
- 8 April 2014
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 48 (5) , 436-444
Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy
The aim of this study was to prospectively verify the relationship between the clinical efficacies of secondary hormone therapy for castration-resistant prostate cancer (CRPC) following first line hormone therapy and neuroendocrine differentiation (NED). Forty-six consecutive patients with CRPC following first line hormone therapy who were treated with flutamide as secondary hormone therapy were prospectively assessed with a median follow-up of 21 months. Serum chromogranin A (CgA), as a marker of NED, was measured using an immunoradiometric assay. Of the 46 patients, 22 (48%) responded to the secondary hormone therapy as a 50% or more reduction from baseline prostate-specific antigen (PSA) with a median response duration of 9.2 months. The PSA response group was correlated with significantly favorable cancer-specific survival (CSS) (92% vs 59% at 5 years, p = 0.0146) compared with the non-response group. Above-normal CgA levels at study entry were detected in 15 patients (33%), but no association with CSS was identified. Data on CgA kinetics were available in 35 patients. The CgA levels before and at 3 months during the treatment were similar. However, eight patients (23%) with an increase in CgA level of a quarter or more from baseline had a tendency for worse CSS (63% vs 84% at 5 years, p = 0.0507) compared with the remaining patients. Within limitations, in this study secondary hormone therapy with flutamide was effective for CRPC following first line hormone therapy. The above-normal CgA level in the first hormone resistance phase is mostly unrelated to prognosis. However, some patients with a remarkable increase in CgA in a short duration may have an unfavorable prognosis caused by NED as well.
- 1 October 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (4)
C123 Risk factors for subsequent development of bladder cancer after surgical management of urothelial carcinoma of the upper urinary tract
- 1 October 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (4)
C123 Risk factors for subsequent development of bladder cancer after surgical management of urothelial carcinoma of the upper urinary tract
- 24 December 2009
- Published by Springer Nature in Medical Molecular Morphology
- Vol. 42 (4) , 239-244
A case of solitary fibrous tumor of the kidney: an immunohistochemical and ultrastructural study with a review of the literature
A solitary fibrous tumor (SFT) is an unusual spindle cell neoplasm that usually arises in the pleura but rarely occurs in the kidney. Despite its rarity, histological diagnosis of SFT is crucial to avoid misdiagnosis with other malignant tumors in the kidney. We report a SFT of the left kidney that presented as a malignant tumor on radiographic findings in a 75-year-old Japanese woman. The tumor was well circumscribed and composed of a mixture of spindle cells and dense collagenous bands with no areas of necrosis or cystic changes noted macroscopically or microscopically. Electron microscopy showed fibroblast-like cells with well-developed rough endoplasmic reticulum, surrounded with collagen fibers. Immunohistochemistry revealed reactivity for vimentin, CD34, Bcl-2, and CD99, but no staining for cytokeratin, S-100, desmin, actin, D2-40, or epithelial membrane antigen (EMA). These findings were compatible with those of SFT. Although SFT of the kidney is extremely rare, this tumor must be included in the differential diagnosis when we encounter renal tumors consisting of mesenchymal elements. Immunohistochemical study is the key to diagnosis for SFT, and ultrastructural study is useful for its diagnosis.
- 24 December 2009
- Published by Springer Nature in Medical Molecular Morphology
- Vol. 42 (4) , 239-244
A case of solitary fibrous tumor of the kidney: an immunohistochemical and ultrastructural study with a review of the literature
A solitary fibrous tumor (SFT) is an unusual spindle cell neoplasm that usually arises in the pleura but rarely occurs in the kidney. Despite its rarity, histological diagnosis of SFT is crucial to avoid misdiagnosis with other malignant tumors in the kidney. We report a SFT of the left kidney that presented as a malignant tumor on radiographic findings in a 75-year-old Japanese woman. The tumor was well circumscribed and composed of a mixture of spindle cells and dense collagenous bands with no areas of necrosis or cystic changes noted macroscopically or microscopically. Electron microscopy showed fibroblast-like cells with well-developed rough endoplasmic reticulum, surrounded with collagen fibers. Immunohistochemistry revealed reactivity for vimentin, CD34, Bcl-2, and CD99, but no staining for cytokeratin, S-100, desmin, actin, D2-40, or epithelial membrane antigen (EMA). These findings were compatible with those of SFT. Although SFT of the kidney is extremely rare, this tumor must be included in the differential diagnosis when we encounter renal tumors consisting of mesenchymal elements. Immunohistochemical study is the key to diagnosis for SFT, and ultrastructural study is useful for its diagnosis.